Free Trial

Trevena (TRVN) Competitors

Trevena logo
$1.06 -0.03 (-2.84%)
As of 05/22/2025 03:31 PM Eastern

TRVN vs. SONN, LIXT, ADIL, CANF, OGEN, MBIO, SPRC, GLTO, SBFM, and IMCC

Should you be buying Trevena stock or one of its competitors? The main competitors of Trevena include Sonnet BioTherapeutics (SONN), Lixte Biotechnology (LIXT), Adial Pharmaceuticals (ADIL), Can-Fite BioPharma (CANF), Oragenics (OGEN), Mustang Bio (MBIO), SciSparc (SPRC), Galecto (GLTO), Sunshine Biopharma (SBFM), and IM Cannabis (IMCC). These companies are all part of the "pharmaceutical products" industry.

Trevena vs.

Sonnet BioTherapeutics (NASDAQ:SONN) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, community ranking, risk, profitability, valuation and earnings.

Trevena's return on equity of 0.00% beat Sonnet BioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Sonnet BioTherapeuticsN/A -408.93% -174.13%
Trevena N/A N/A -119.55%

Sonnet BioTherapeutics has higher revenue and earnings than Trevena.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sonnet BioTherapeutics$1M3.55-$7.44MN/AN/A
Trevena$443K2.29-$40.29M-$47.04-0.02

9.4% of Sonnet BioTherapeutics shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 2.0% of Sonnet BioTherapeutics shares are held by insiders. Comparatively, 2.7% of Trevena shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Sonnet BioTherapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Trevena has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.

Sonnet BioTherapeutics presently has a consensus target price of $20.00, indicating a potential upside of 1,685.71%. Trevena has a consensus target price of $5.00, indicating a potential upside of 372.14%. Given Sonnet BioTherapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Sonnet BioTherapeutics is more favorable than Trevena.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sonnet BioTherapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Trevena
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Trevena had 1 more articles in the media than Sonnet BioTherapeutics. MarketBeat recorded 1 mentions for Trevena and 0 mentions for Sonnet BioTherapeutics. Trevena's average media sentiment score of 0.87 beat Sonnet BioTherapeutics' score of 0.00 indicating that Trevena is being referred to more favorably in the news media.

Company Overall Sentiment
Sonnet BioTherapeutics Neutral
Trevena Positive

Trevena received 594 more outperform votes than Sonnet BioTherapeutics when rated by MarketBeat users. However, 84.62% of users gave Sonnet BioTherapeutics an outperform vote while only 68.14% of users gave Trevena an outperform vote.

CompanyUnderperformOutperform
Sonnet BioTherapeuticsOutperform Votes
22
84.62%
Underperform Votes
4
15.38%
TrevenaOutperform Votes
616
68.14%
Underperform Votes
288
31.86%

Summary

Sonnet BioTherapeutics beats Trevena on 8 of the 15 factors compared between the two stocks.

Get Trevena News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRVN vs. The Competition

MetricTrevenaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.02M$6.47B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-0.029.0626.7119.71
Price / Sales2.29251.51386.08120.53
Price / CashN/A65.8538.2534.62
Price / Book-0.106.456.774.50
Net Income-$40.29M$143.98M$3.23B$248.22M
7 Day Performance-15.28%0.38%0.48%-0.78%
1 Month Performance-8.71%2.14%9.10%11.53%
1 Year Performance-89.84%-0.33%18.56%8.99%

Trevena Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TRVN
Trevena
1.3198 of 5 stars
$1.06
-2.8%
$5.00
+372.1%
-89.7%$1.02M$443,000.00-0.0240Analyst Forecast
SONN
Sonnet BioTherapeutics
2.0418 of 5 stars
$1.33
+3.9%
$20.00
+1,403.8%
-35.6%$4.08M$1M0.0010
LIXT
Lixte Biotechnology
0.3311 of 5 stars
$1.28
+5.3%
N/A-48.1%$4.03MN/A-0.744Positive News
ADIL
Adial Pharmaceuticals
3.239 of 5 stars
$0.61
+1.6%
$8.00
+1,209.3%
-49.4%$4.02MN/A-0.1820Analyst Revision
CANF
Can-Fite BioPharma
N/A$1.10
-0.9%
$14.00
+1,172.7%
-56.3%$3.89M$674,000.00-0.618
OGEN
Oragenics
N/A$0.18
+6.8%
N/A-92.3%$3.87M$40,000.00-0.035
MBIO
Mustang Bio
0.0933 of 5 stars
$1.13
-3.0%
$100.00
+8,749.6%
-89.3%$3.85MN/A-0.01100Positive News
Gap Down
SPRC
SciSparc
0.6424 of 5 stars
$0.35
+2.3%
N/A-73.5%$3.81M$1.31M0.004
GLTO
Galecto
1.6497 of 5 stars
$2.78
+1.3%
$10.00
+260.4%
-80.9%$3.67MN/A-0.1440Gap Down
SBFM
Sunshine Biopharma
1.8404 of 5 stars
$1.35
+8.0%
$15.00
+1,011.1%
+74.5%$3.65M$34.87M-0.013Earnings Report
Gap Down
IMCC
IM Cannabis
0.5043 of 5 stars
$1.61
-2.4%
N/A-52.6%$3.60M$54.03M-0.47340Positive News
Earnings Report
Gap Down

Related Companies and Tools


This page (NASDAQ:TRVN) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners